

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	103	514/273.CCLS.	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT	OR	ON	2006/12/13 18:04
L2	1380	514/275.CCLS.	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT	OR	ON	2006/12/13 18:05
L3	2805	514/256.CCLS.	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT	OR	ON	2006/12/13 18:05
L5	998	514/278.CCLS.	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT	OR	ON	2006/12/13 18:05
L6	1080	514/367.CCLS.	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT	OR	ON	2006/12/13 18:05
L7	733	514/370.CCLS.	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT	OR	ON	2006/12/13 18:05
L8	797	514/375.CCLS.	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT	OR	ON	2006/12/13 18:05
L9	472	514/389.CCLS.	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT	OR	ON	2006/12/13 18:05
L10	358	514/392.CCLS.	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT	OR	ON	2006/12/13 18:05

EAST Search History

L11	497	544/230.CCLS.	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT	OR	ON	2006/12/13 18:05
L12	741	546/15.CCLS.	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT	OR	ON	2006/12/13 18:05
L13	289	546/17.CCLS.	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT	OR	ON	2006/12/13 18:06
L14	172	548/147.CCLS.	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT	OR	ON	2006/12/13 18:06
L15	275	548/216.CCLS.	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT	OR	ON	2006/12/13 18:06
L16	180	548/301.1.CCLS.	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT	OR	ON	2006/12/13 18:06
L17	8957	L1 OR L2 OR L3 OR L5 OR L6 OR L7 OR L8 OR L9 OR L10 OR L11 OR L12 OR L13 OR L14 OR L15 OR L16	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT	OR	ON	2006/12/13 18:07
L18	36	L17 AND CGRP	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT	OR	ON	2006/12/13 18:07

STN Structure Search (Registry | Caplus)

10/549, 338 & 10/547, 227

12/13/2006

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 10:18:22 ON 13 DEC 2006

=> fil reg
COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE ENTRY 0.21	TOTAL SESSION 0.21
-----------------------------	--------------------------

FILE 'REGISTRY' ENTERED AT 10:18:29 ON 13 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 DEC 2006 HIGHEST RN 915277-53-1
DICTIONARY FILE UPDATES: 12 DEC 2006 HIGHEST RN 915277-53-1

New CAS Information Use Policies - enter HELP USAGETERMS for details


TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/reqprops.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10549338\1.str



```
chain nodes :  
14 15 16 18 .19 20 21  
ring nodes :
```


1 2 3 4 5 6 7 8 9 10 11 12 13 17 28 29
 chain bonds :
 2-14 10-20 11-21 12-19 14-15 15-16 15-18 16-17
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 8-10 8-13 10-11 10-20 11-12 12-13
 17-28 17-29
 exact/norm bonds :
 2-14 5-6 5-7 6-9 7-8 8-9 8-10 8-13 10-11 10-20 11-12 12-13 12-19 14-15
 15-18 16-17 17-28 17-29
 exact bonds :
 11-21 15-16
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5

Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 11:Atom 12:Atom 13:Atom 14:CLASS 15:CLASS 16:CLASS 17:Atom 18:CLASS
 19:CLASS 20:CLASS 21:CLASS 28:Atom 29:Atom

L1 STRUCTURE UPLOADED

=> d
 L1 HAS NO ANSWERS
 L1 STR

Must be a ring




Structure attributes must be viewed using STN Express query preparation.

=> s 11 full
 FULL SEARCH INITIATED 10:18:47 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 1851 TO ITERATE
 100.0% PROCESSED 1851 ITERATIONS
 SEARCH TIME: 00.00.01

L2 116 SEA SSS FUL L1

=>
 Uploading C:\Program Files\Stnexp\Queries\10547227\2.str

116 ANSWERS



chain nodes :

14 15 16 18 19 20

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 17 27 28

chain bonds :

2-14 10-19 11-20 12-18 14-15 15-16 16-17

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 8-10 8-13 10-11 11-12 12-13

17-27 17-28

exact/norm bonds :

2-14 5-6 5-7 6-9 7-8 8-9 8-10 8-13 10-11 10-19 11-12 12-13 12-18 14-15
15-16 16-17 17-27 17-28

exact bonds :

11-20

normalized bonds :

1-2 1-6 2-3 3-4 4-5

G1:SO2,C



Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:CLASS 15:CLASS 16:CLASS 17:Atom 18:CLASS
19:CLASS 20:CLASS 27:Atom 28:Atom

L3 STRUCTURE UPLOADED

=>

Uploading C:\Program Files\Stnexp\Queries\10547227\3.str



chain nodes :

14 15 16 18 19 20

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 17 25 26

chain bonds :

2-14 10-19 11-20 12-18 14-15 15-16 16-17

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 8-10 8-13 10-11 11-12 12-13
17-25 17-26

exact/norm bonds :

2-14 5-6 5-7 6-9 7-8 8-9 8-10 8-13 10-11 10-19 11-12 12-13 12-18 14-15
15-16 16-17 17-25 17-26

exact bonds :

11-20

normalized bonds :

1-2 1-6 2-3 3-4 4-5


G1:SO2,C

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 11:Atom 12:Atom 13:Atom 14:CLASS 15:CLASS 16:CLASS 17:Atom 18:CLASS
 19:CLASS 20:CLASS 25:Atom 26:Atom

L4 STRUCTURE UPLOADED

=> d
 L4 HAS NO ANSWERS
 L4 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 14 full
 FULL SEARCH INITIATED 10:24:08 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 2767 TO ITERATE

100.0% PROCESSED 2767 ITERATIONS
 SEARCH TIME: 00.00.01

40 ANSWERS

L5 40 SEA SSS FUL L4

=> fil caplus	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	337.40	337.61

FILE 'CAPLUS' ENTERED AT 10:24:13 ON 13 DEC 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is

strictly prohibited.

FILE COVERS 1907 - 13 Dec 2006 VOL 145 ISS 25
FILE LAST UPDATED: 12 Dec 2006 (20061212/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> d his

(FILE 'HOME' ENTERED AT 10:18:22 ON 13 DEC 2006)

FILE 'REGISTRY' ENTERED AT 10:18:29 ON 13 DEC 2006

L1 STRUCTURE UPLOADED
L2 116 S L1 FULL
L3 STRUCTURE UPLOADED
L4 STRUCTURE UPLOADED
L5 40 S L4 FULL

FILE 'CAPLUS' ENTERED AT 10:24:13 ON 13 DEC 2006

=> s 12
L6 3 L2

=> s 15
L7 7 L5

=> d ibib abs hitstr L6 1-3



L6 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2006266946 CAPLUS
 DOCUMENT NUMBER: 144:331434
 TITLE: Preparation of tricyclic anilide spirohydantoin CGRP receptor antagonists
 INVENTOR(S): Bell, Ian M.; Gallicchio, Steven N.; Zartman, C.
 Blair; Theberge, Cory R.; Zhang, Xufang
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA
 SOURCE: PCT Int. Appl., 64 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006031676	A2	20060323	WO 2005-US322880	20050909
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRIORITY APPLN. INFO.: US 2004-609294P			P 20040913	

OTHER SOURCE(S): MARPAT 144:331434
 GI

Inventors

L6 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




AB Title compds. I [A1 and A2 independently = bond or CR1R14, where one of A1 and A2 is optionally absent; B1 and B4 independently = C when double bond present, CR1 or N; B2 and B3 independently = bond, CR1R2, CO, CS, O, S, etc., where one of B2 and B3 is optionally absent; D1 and D2 independently = O, S, SO₂, CR1R2, CO, etc.; T, U and V independently = "C(R1)- and -N=" wherein at least one of T, U, and V = "C(R1)-"; W, X, Y, and Z = bond, CR1R2, CS, O, etc.; R1 and R2 = H, (un)substituted alkyl, cycloalkyl, alkyanyl, etc.; R4 = H, (un)substituted alkyl, benzyl, etc.; R5a, R5b, and R5c = H, alkyl, alkoxy, halo, etc.; R6 = H, (un)substituted alkyl, cycloalkyl, etc.; R13 = H, OH, halo, and their pharmaceutically acceptable salts, useful as antagonists of calcitonin gene-related peptide (CGRP) receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. Thus, e.g., II was prepared by reaction of (-)-5'-amino-3-methylspiro[imidazolidine-4,2'-(2H-inden)-2,5-dione (preparation given) with sodium (2,5-dioxo-5,6-dihydro-4H-imidazo[1,5,4-de]quinoxalin-1(2H)-yl)acetate (preparation given). I demonstrated activity as antagonists of the CGRP receptor with Ki or IC50 values generally less than about 50 nM. The invention is also directed to pharmaceutical compns. comprising these compds. and the use of these compds. and compns. in the prevention or treatment of such diseases in which CGRP is involved.

IT 880090-65-3P 880090-66-4P 880090-67-5P
 880090-68-6P 880090-69-7P 880090-70-0P
 880090-71-1P 880090-72-2P 880090-73-3P
 880090-74-4P 880090-75-5P 880090-76-6P
 880090-77-7P 880090-78-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

L6 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prep. of tricyclic anilide spirohydantoin CGRP receptor antagonists)

RN 880090-65-3 CAPLUS
 CN 4H-Imidazo[1,5,4-de]quinoxaline-1(2H)-acetamide,
 N-(1',3'-dihydro-3-methyl-
 2,5-dioxospiro[imidazolidine-4,2'-(2H-inden)-5'-yl]-5,6-dihydro-2,5-dioxo- (9CI) (CA INDEX NAME)




RN 880090-66-4 CAPLUS
 CN 4H-Imidazo[1,5,4-de]quinoxaline-1(2H)-acetamide,
 N-(1',3'-dihydro-3-methyl-
 2,5-dioxospiro[imidazolidine-4,2'-(2H-inden)-5'-yl]-5,6-dihydro-6-methyl-
 2,5-dioxo- (9CI) (CA INDEX NAME)




RN 880090-67-5 CAPLUS
 CN Pyrrolo[4,3,2-de]quinoline-1(3H)-acetamide,
 N-(1',3'-dihydro-3-methyl-
 2,5-dioxospiro[imidazolidine-4,2'-(2H-inden)-5'-yl]-4,5-dihydro-4-oxo- (9CI) (CA INDEX NAME)

L6 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 880090-68-6 CAPLUS
 CN 4H-Imidazo[1,5,4-de]quinoxaline-1(2H)-acetamide,
 N-(1',3'-dihydro-3-methyl-
 2,5-dioxospiro[imidazolidine-4,2'-(2H-inden)-5'-yl]-5,6-dihydro-8-methyl-
 2,5-dioxo- (9CI) (CA INDEX NAME)



RN 880090-69-7 CAPLUS
 CN 4H-Imidazo[1,5,4-de]quinoxaline-1(2H)-acetamide,
 N-(1',3'-dihydro-3-methyl-
 2,5-dioxospiro[imidazolidine-4,2'-(2H-inden)-5'-yl]-5,6-dihydro-6,8-dimethyl-
 2,5-dioxo- (9CI) (CA INDEX NAME)


L6 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)



RN 880090-70-0 CAPLUS
CN 4H-Imidazo[1,5,4-de]quinoxaline-1(2H)-acetamide,
7-chloro-N-(1',3'-dihydro-

3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl]-5,6-dihydro-8-
methyl-2,5-dioxo- (9CI) (CA INDEX NAME)




RN 880090-71-1 CAPLUS
CN 4H-Imidazo[1,5,4-de]quinoxaline-1(2H)-acetamide,
N-(1',3'-dihydro-3-methyl-

2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl]-5,6-dihydro-2,5-dioxo-
6-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)


L6 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)



RN 880090-72-2 CAPLUS
CN 4H-Imidazo[1,5,4-de]quinoxaline-1(2H)-acetamide,
N-(1',3'-dihydro-3-methyl-

2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl]-5,6-dihydro-2,5-dioxo-
6-phenyl- (9CI) (CA INDEX NAME)




RN 880090-73-3 CAPLUS
CN 4H-Imidazo[1,5,4-de]quinoxaline-1(2H)-acetamide,
N-(1',3'-dihydro-3-methyl-


2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl]-5,6-dihydro-7-methyl-
2,5-dioxo- (9CI) (CA INDEX NAME)

L6 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)




RN 880090-74-4 CAPLUS
CN 4H-Imidazo[1,5,4-fg][1,6]benzodiazocine-1(2H)-acetamide,
N-(1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-
yl)-5,6,7,8-tetrahydro-2,7-dioxo- (9CI) (CA INDEX NAME)



RN 880090-75-5 CAPLUS
CN 4H-Imidazo[1,5,4-fg][1,6]benzodiazocine-1(2H)-acetamide,
N-(1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-
yl)-5,6,7,8-tetrahydro-8-methyl-2,7-dioxo- (9CI) (CA INDEX NAME)


L6 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)



RN 880090-76-6 CAPLUS
CN Pyrrolo[4,3,2-de]quinoline-1(3H)-acetamide,
N-(1',3'-dihydro-3-methyl-2,5-

dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl]-4,5-dihydro-7-methyl-4-oxo-
(9CI) (CA INDEX NAME)




RN 880090-77-7 CAPLUS
CN Pyrrolo[4,3,2-de]quinoline-1(2H)-acetamide,
N-(1',3'-dihydro-3-methyl-2,5-

dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl]-2a,3,4,5-tetrahydro-4-oxo-
(9CI) (CA INDEX NAME)


L6 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)



RN 880090-78-8 CAPLUS

CN Pyrrolo[4,3,2-d]quinoline-1(2H)-acetamide, N-(1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-2a,3,4,5-tetrahydro-5-methyl-4-oxo- (9CI) (CA INDEX NAME)



L6 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

AB Title compds. [I; B = (substituted) imidazolyl, pyrrolyl, pyrazolyl, triazolyl, 2-oxoimidazolyl, 2-oxooxazolyl, 2-oxothiazolyl, 2-oxodiazepanyl, etc.]: Al, A2 = bond, CR13R14, null; R13, R14 = H, (fluoro)alkyl, OH; R4 = H, (fluoro)alkyl; R5a, R5b, R5c = H, alkyl, alkoxy, OCF3, CF3, halo, OH, cyano; R6 = H, (substituted) alkyl, Ph, pyridyl, pyrimidinyl, pyrazinyl, thienyl; m, n = 1, 2], were prepared

Thus,

3-chlorobenzoic acid, 6'-amino-3',4'-dihydro-1'H-spiro[imidazolidine-4,2'-naphthalenel]-2,5-dione, EDC, HOBT, and diisopropylamine were stirred together for 10 h in DMF at ambient temperature to give 6'-(3'-chlorobenzoyl)amino-3',4'-dihydro-1'H-spiro[imidazolidine-4,2'-naphthalenel]-2,5-dione. I generally showed CGRP antagonistic activity with Ki or IC50 values of ≤50 nM.

IT 766536-27-0P 766536-28-1P 766536-29-2P

766536-30-5P 766536-31-6P 766536-32-7P

766536-33-8P 766536-34-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of spirohydantoin anilides as calcitonin gene-related peptide receptor antagonists)

RN 766536-27-0 CAPLUS


CN 3-Oxazolidineacetamide, N-(3',4'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(1'H)-naphthalen]-6'-yl)-4-(1-methylethyl)-2-oxo-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 766536-28-1 CAPLUS

CN 1H-Imidazole-1-acetamide, N-(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-4-phenyl- (9CI) (CA INDEX NAME)



RN 766536-29-2 CAPLUS

CN 3-Oxazolidineacetamide, N-(3',4'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(1'H)-naphthalen]-6'-yl)-2-oxo-4-(phenylmethyl)-, (4S)- (9CI) (CA INDEX NAME)

L6 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:799568 CAPLUS

DOCUMENT NUMBER: 141:31A503

TITLE: Preparation of spirohydantoin anilides as calcitonin gene-related peptide (CGRP) receptor antagonists

INVENTOR(S): Bell, Ian M.; Theberge, Cory R.; Williams, Theresa M.; Zartman, C. Blair; Zhang, Xu-fang; Gallicchio, Steven N.

PATENT ASSIGNEE(S): Merck & Co. Inc., USA

SOURCE: PCT Int. Appl., 61 PP.

CODEN: PIXKD2


DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004083187	A1	20040930	WO 2004-US7678	20040310
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, SD, SL, SZ, T2, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CG, CI, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
AU 2004221891	A1	20040930	AU 2004-221891	20040310
CA 2518852	AA	20040930	CA 2004-2518852	20040310
EP 1606264	A1	20051221	EP 2004-719323	20040310
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, SE, HU, PL, SK				
JP 2006520387	T2	20060907	JP 2006-507138	20040310
US 2006148779	A1	20060706	US 2005-547082	20050826
			US 2003-454944P	20030314
PRIORITY APPLN. INFO.:				
			WO 2004-US7678	A 20040310

OTHER SOURCE(S): MARPAT 141:314326
GI*B = monocyclic thru N*L6 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
INDEX NAME)

Absolute stereochemistry.

RN 766536-30-5 CAPLUS
CN 1H-1,3-Diazepine-1-acetamide, 3-(cyclopropylmethyl)-N-(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)hexahydro-2-oxo- (9CI) (CA INDEX NAME)RN 766536-31-6 CAPLUS
CN 3-Oxazolidineacetamide, N-(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-2-oxo-4-phenyl-, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

RN 766536-32-7 CAPLUS
CN 1H-Imidazole-1-acetamide, 3-(cyclopropylmethyl)-N-(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-2-oxo-4-phenyl-, (4S)- (9CI) (CA INDEX NAME)


Searched by Jason M. Nolan, Ph.D. Page 10

L6 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
(9CI) (CA INDEX NAME)


(Continued)



RN 766536-33-8 CAPLUS
 CN 1-imidazolidineacetamide, N-(1',3'-dihydro-3-methyl-2,5-dioxospiro(imidazolidine-4,2'-(2H)inden)-5'-yl)-2-oxo-3-(2-pyridinyl)-(9CI) (CA INDEX NAME)



RN 766536-34-9 CAPLUS
 CN 3-Oxazolidineacetamide,
 N-(1',3'-dihydro-2,5-dioxospiro(imidazolidine-4,2'-(2H)inden)-5'-yl)-2-oxo-5-phenyl-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004-799443 CAPLUS

DOCUMENT NUMBER: 141:314324

TITLE: Preparation of bicyclic anilide spirohydantoin CGRP receptor antagonists

INVENTOR(S): Bell, Ian M.; Galicchio, Steven N.; Theberge, Cory R.; Zhang, Yu-Fang; Stump, Craig; Zartman, C. Blair

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

PCT Int. Appl., 120 PP.

CODEN: PIXHD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004082605	A2	20040930	WO 2004-US7289	20040310
WO 2004082605	A3	20041118		
W: AE, AG, AL, AM, AT, AU, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TZ, UG, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW				
EP: BE, BG, CH, DE, DK, ES, FR, GB, GR, IE, SI, LT, LV, FI, RO, MK, CY				
EP 1608627	A2	20051228	EP 2004-719222	20040310
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, SI, LT, LV, FI, RO, MK, CY				
JP 2006520383	T2	20060907	JP 2006-507033	20040310
US 2006211712	A1	20060921	US 2005-549338	20050913
			US 2003-455609P	20030314
			US 2003-486642P	P 20030711
			WO 2004-US7289	A 20040310

PRIORITY APPLN. INFO.: MARPAT 141:314324
GI

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



B = bicyclic
 thru
 -N

II

AB The title compds. [I]; B = (un)substituted bicycloheterocycle; A1, A2 = a bond, (un)substituted CH₂; R₄ = H, alkyl, fluoroalkyl, cycloalkyl, etc.; R₅₁, R₅₂, R₅₃ = H, alkyl, alkoxy, etc.; R₆ = H, alkyl, cycloalkyl, etc.; m, n = 1-2] that are antagonists of CGRP receptors and that are useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache, were prepared. E.g., a multi-step synthesis of II, starting from 6-bromo-2-tetralone, was given. The exemplified compds. I had activity as antagonists of the CGRP receptor, generally with a K_i or IC₅₀ value of <50μM. The invention is also directed to pharmaceutical compns. comprising the compds. I and the use of these compds. and compns. in the prevention or treatment of such diseases in which CGRP is involved.


IT 767303-71-9P 767303-73-1P 767303-75-3P
 767303-77-5P 767303-78-6P 767303-79-7P
 767303-80-0P 767303-81-1P 767303-82-2P
 767303-83-3P 767303-85-5P 767303-86-6P
 767303-87-7P 767303-88-8P 767303-89-9P
 767303-90-2P 767303-91-3P 767303-92-4P
 767303-93-5P 767303-94-6P 767303-95-7P
 767303-96-8P 767303-97-9P 767303-98-0P
 767303-99-1P 767304-00-7P 767304-01-8P
 767304-02-9P 767304-03-0P 767304-04-1P
 767304-05-2P 767304-06-3P 767304-07-4P
 767304-08-5P 767304-09-6P 767304-10-9P
 767304-11-0P 767304-12-1P 767304-13-2P
 767304-14-3P 767304-15-4P 767304-16-5P
 767304-17-6P 767304-18-7P 767304-19-8P
 767304-20-1P 767304-21-2P 767304-22-3P
 767304-23-4P 767304-24-5P 767304-25-6P
 767304-26-7P 767304-27-8P 767304-28-9P
 767304-29-0P 767304-30-3P 767304-31-4P
 767304-32-5P 767304-33-6P 767304-34-7P
 767304-35-8P 767304-36-9P 767304-37-0P
 767304-38-1P 767304-39-2P 767304-40-5P

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


767304-41-6P 767304-42-7P 767304-43-8P
 767304-44-9P 767304-45-0P 767304-46-1P
 767304-47-2P 767304-48-3P 767304-49-4P
 767304-50-7P 767304-51-8P 767304-52-9P
 767304-53-0P 767304-54-1P 767304-55-2P
 767304-56-3P 767304-57-4P 767304-58-5P
 767304-59-6P 767304-60-9P 767304-61-0P
 767304-62-1P 767304-63-2P 767304-64-3P
 767304-65-4P 767304-66-5P 767305-84-0P
 767305-85-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (Prepn. of bicyclic anilide spirohydantoin CGRP receptor antagonists)

RN 767303-71-9 CAPLUS
 CN 1H-Benzimidazole-1-acetamide, N-(3',4'-dihydro-2,5-dioxospiro(imidazolidine-4,2'-(1'H)-naphthalen)-6'-yl)-2,3-dihydro-2-oxo-(9CI) (CA INDEX NAME)




RN 767303-73-1 CAPLUS
 CN 1H-Indole-1-acetamide, N-(3',4'-dihydro-2,5-dioxospiro(imidazolidine-4,2'-(1'H)-naphthalen)-6'-yl)-2,3-dihydro-2-oxo-(9CI) (CA INDEX NAME)




RN 767303-75-3 CAPLUS
 CN Spiro[3H-indole-3,4'-piperidine]-1(2H)-acetamide, N-(3',4'-dihydro-2,5-dioxospiro(imidazolidine-4,2'-(1'H)-naphthalen)-6'-yl)-2-oxo-(9CI) (CA INDEX NAME)

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN


(Continued)



RN 767303-77-5 CAPLUS
CN 1H-Benzimidazole-1-acetamide, N-(3',4'-dihydro-2,5-dioxospiro[imidazolidine-4,2'(1'H)-naphthalen]-6'-yl)-2,3-dihydro-2-oxo-(9CI) (CA INDEX NAME)




RN 767303-78-6 CAPLUS
CN 1H-Benzimidazole-1-acetamide, N-(3',4'-dihydro-2,5-dioxospiro[imidazolidine-4,2'(1'H)-naphthalen]-6'-yl)-2,3-dihydro-3-methyl-2-oxo-(9CI) (CA INDEX NAME)




RN 767303-79-7 CAPLUS
CN 1H-Benzimidazole-1-acetamide, N-(3',4'-dihydro-2,5-dioxospiro[imidazolidine-4,2'(1'H)-naphthalen]-6'-yl)-3-ethyl-2,3-dihydro-

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
2-oxo-(9CI) (CA INDEX NAME)


(Continued)



RN 767303-80-0 CAPLUS
CN 3(2H)-Benzoxazoleacetamide, N-(3',4'-dihydro-2,5-dioxospiro[imidazolidine-4,2'(1'H)-naphthalen]-6'-yl)-2-oxo-(9CI) (CA INDEX NAME)




RN 767303-81-1 CAPLUS
CN 3(2H)-Benzoxazoleacetamide, N-(3',4'-dihydro-2,5-dioxospiro[imidazolidine-4,2'(1'H)-naphthalen]-6'-yl)-5-methyl-2-oxo-(9CI) (CA INDEX NAME)




RN 767303-82-2 CAPLUS
CN Naphth[2,1-d]oxazole-3(2H)-acetamide, N-(3',4'-dihydro-2,5-dioxospiro[imidazolidine-4,2'(1'H)-naphthalen]-6'-yl)-2-oxo-(9CI) (CA INDEX NAME)


L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 767303-83-3 CAPLUS
CN 1H-Benzimidazole-1-acetamide, N-(3',4'-dihydro-2,5-dioxospiro[imidazolidine-4,2'(1'H)-naphthalen]-6'-yl)-(9CI) (CA INDEX NAME)




RN 767303-85-5 CAPLUS
CN 1H-Benzimidazole-1-acetamide, N-(3',4'-dihydro-2,5-dioxospiro[imidazolidine-4,2'(1'H)-naphthalen]-6'-yl)-2-phenyl-(9CI) (CA INDEX NAME)




RN 767303-86-6 CAPLUS
CN 3(2H)-Benzoxazoleacetamide, 5-chloro-N-(3',4'-dihydro-2,5-dioxospiro[imidazolidine-4,2'(1'H)-naphthalen]-6'-yl)-2-oxo-(9CI) (CA INDEX NAME)


L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 767303-87-7 CAPLUS
CN 3(2H)-Benzoxazoleacetamide, N-(3',4'-dihydro-2,5-dioxospiro[imidazolidine-4,2'(1'H)-naphthalen]-6'-yl)-6-hydroxy-2-oxo-(9CI) (CA INDEX NAME)




RN 767303-88-8 CAPLUS
CN 1H-Benzimidazole-1-acetamide, N-(3',4'-dihydro-2,5-dioxospiro[imidazolidine-4,2'(1'H)-naphthalen]-6'-yl)-2,3-dihydro-2-oxo-3-(phenylmethyl)-(9CI) (CA INDEX NAME)




RN 767303-89-9 CAPLUS
CN 1-Piperidinocarboxylic acid, 4-[3-{2-[{(3',4'-dihydro-2,5-dioxospiro[imidazolidine-4,2'(1'H)-naphthalen]-6'-yl}amino]-2-oxoethyl}-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)




RN 767303-90-2 CAPLUS
CN 1H-Benzimidazole-1-acetamide, N-(3',4'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(1'H)-naphthalen]-5'-yl)-2,3-dihydro-2-oxo-3-(4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 767303-91-3 CAPLUS
CN 3(2H)-Benzoxazoleacetamide, N-(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2Hinden)-5'-yl]-7-fluoro-2-oxo- (9CI) (CA INDEX NAME)


L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 3(2H)-Benzoxazoleacetamide, 5-chloro-N-(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2Hinden)-5'-yl]-2-oxo- (9CI) (CA INDEX NAME)



RN 767303-95-7 CAPLUS
CN 1H-Benzimidazole-1-acetamide, N-(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2Hinden)-5'-yl]- (9CI) (CA INDEX NAME)




RN 767303-96-8 CAPLUS
CN 3(2H)-Benzoxazolepropanamide, N-(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2Hinden)-5'-yl]-2-oxo- (9CI) (CA INDEX NAME)




RN 767303-97-9 CAPLUS
CN 1H-Benzimidazole-1-acetic acid, 3-[2-[(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2Hinden)-5'-yl]amino)-2-oxoethyl]-2,3-dihydro-2-oxo-, methyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN


(Continued)



RN 767303-92-4 CAPLUS
CN 1H-Benzimidazole-1-acetamide, N-(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2Hinden)-5'-yl]-2,3-dihydro-4,6-dimethyl-2-oxo- (9CI) (CA INDEX NAME)




RN 767303-93-5 CAPLUS
CN 3(2H)-Benzoxazoleacetamide, N-(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2Hinden)-5'-yl]-2-oxo- (9CI) (CA INDEX NAME)




RN 767303-94-6 CAPLUS


L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 767303-98-0 CAPLUS
CN 3(2H)-Benzoxazoleacetamide, N-(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2Hinden)-5'-yl]-6-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 767303-99-1 CAPLUS
CN 3(2H)-Benzoxazoleacetamide, N-(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2Hinden)-5'-yl]-6-hydroxy-2-oxo- (9CI) (CA INDEX NAME)




RN 767304-00-7 CAPLUS
CN Naphth[2,1-d]oxazole-3(2H)-acetamide, N-(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2Hinden)-5'-yl]-2-oxo- (9CI) (CA INDEX NAME)

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN


(Continued)



RN 767304-01-8 CAPLUS
CN 1H-Benzimidazole-1-acetamide, N-(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 767304-02-9 CAPLUS
CN 1H-Benzimidazole-1-acetamide, N-(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-2,3-dihydro-3-methyl-2-oxo- (9CI) (CA INDEX NAME)




L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 767304-03-0 CAPLUS
CN 1H-Benzimidazole-1-acetamide, N-(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-3-ethyl-2,3-dihydro-2-oxo-

(9CI) (CA INDEX NAME)




RN 767304-04-1 CAPLUS
CN 1H-Benzimidazole-1-acetic acid, 3-[2-[(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)amino]-2-oxoethyl]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 767304-05-2 CAPLUS
CN 3(2H)-Benzoxazoleacetamide,
N-(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-5-methyl-2-oxo- (9CI) (CA INDEX NAME)


L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 767304-06-3 CAPLUS
CN 1H-Benzimidazole-1-acetamide, N-(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 767304-07-4 CAPLUS
CN 1H-Indole-1-acetamide,
N-(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)- (9CI) (CA INDEX NAME)




RN 767304-08-5 CAPLUS
CN Naphth[2,3-d]oxazole-3(2H)-acetamide, N-(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-5,6,7,8-tetrahydro-2-oxo- (9CI) (CA INDEX NAME)


L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 767304-09-6 CAPLUS
CN Naphth[1,2-d]oxazole-1(2H)-acetamide, N-(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-2-oxo- (9CI) (CA INDEX NAME)




RN 767304-10-9 CAPLUS
CN 3(2H)-Benzoxazoleacetamide,
N-(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-5,7-dimethyl-2-oxo- (9CI) (CA INDEX NAME)




RN 767304-11-0 CAPLUS
CN 3(2H)-Benzoxazoleacetamide,
N-(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-6-methoxy-2-oxo- (9CI) (CA INDEX NAME)

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN


(Continued)



RN 767304-12-1 CAPLUS
CN 3(2H)-Benzoxazoleacetamide, 5-chloro-N-(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-6-hydroxy-2-oxo- (9CI)
(CA INDEX NAME)




RN 767304-13-2 CAPLUS
CN 3(2H)-Benzoxazoleacetamide, 5,7-dibromo-N-(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-6-hydroxy-2-oxo- (9CI)
(CA INDEX NAME)




RN 767304-14-3 CAPLUS
CN 3(2H)-Benzoxazoleacetamide, 5-bromo-N-(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-6-hydroxy-2-oxo- (9CI)
(CA INDEX NAME)

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN


(Continued)



RN 767304-15-4 CAPLUS
CN 3(2H)-Benzoxazoleacetamide, N-(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-4-methyl-2-oxo- (9CI)
(CA INDEX NAME)




RN 767304-16-5 CAPLUS
CN 3(2H)-Benzoxazoleacetamide, 5-amino-N-(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-2-oxo- (9CI)
(CA INDEX NAME)




RN 767304-17-6 CAPLUS
CN 3(2H)-Benzothiazoleacetamide, N-(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-2-oxo- (9CI)
(CA INDEX NAME)

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN


(Continued)



RN 767304-18-7 CAPLUS
CN 1H-Indole-1-acetamide,
N-(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-2,3-dihydro-2-oxo- (9CI)
(CA INDEX NAME)




RN 767304-19-8 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine]-1(2H)-acetamide, N-(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-2-oxo- (9CI)
(CA INDEX NAME)




RN 767304-20-1 CAPLUS
CN 1H-Benzimidazole-1-acetamide, N-(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-2,3-dihydro-2-oxo-3-(4-piperidinyl)- (9CI)
(CA INDEX NAME)

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)




RN 767304-21-2 CAPLUS
CN 1H-Benzimidazole-1-acetamide, N-(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-2,3-dihydro-4,6-dimethyl-2-oxo-3-[2-oxo-2-(1-pyrrolidinyl)ethyl]- (9CI)
(CA INDEX NAME)




RN 767304-22-3 CAPLUS
CN 3(2H)-Benzoxazoleacetamide,
N-(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-N,5,7-trimethyl-2-oxo- (9CI)
(CA INDEX NAME)

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)




RN 767304-23-4 CAPLUS
CN 1H-Benzimidazole-3,4'-piperidine-1(2H)-acetamide, N-(1',3'-dihydro-3-methyl-2,5-dioxospiro(imidazolidine-4,2'-(2H)inden)-5'-yl)-2-oxo-1'-phenylmethyl- (9CI) (CA INDEX NAME)




RN 767304-24-5 CAPLUS
CN 1H-Benzimidazole-1-acetamide, N-(1',3'-dihydro-3-methyl-2,5-dioxospiro(imidazolidine-4,2'-(2H)inden)-5'-yl)-2,3-dihydro-2-oxo-3-(2-pyridinyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)




RN 767304-25-6 CAPLUS
CN 1H-Benzimidazole-1-acetamide, N-(1',3'-dihydro-3-methyl-2,5-dioxospiro(imidazolidine-4,2'-(2H)inden)-5'-yl)-2,3-dihydro-2-oxo-3-(5-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 767304-26-7 CAPLUS
CN 1H-Benzimidazole-1-acetamide, N-(1',3'-dihydro-3-methyl-2,5-dioxospiro(imidazolidine-4,2'-(2H)inden)-5'-yl)-2,3-dihydro-2-oxo-3-(2-thiazolyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)




RN 767304-27-8 CAPLUS
CN 1H-Benzimidazole-1-acetamide, N-(1',3'-dihydro-3-methyl-2,5-dioxospiro(imidazolidine-4,2'-(2H)inden)-5'-yl)-2,3-dihydro-2-oxo-3-pyrazinyl- (9CI) (CA INDEX NAME)




RN 767304-28-9 CAPLUS
CN 1H-Benzimidazole-1-acetamide, N-(1',3'-dihydro-3-methyl-2,5-dioxospiro(imidazolidine-4,2'-(2H)inden)-5'-yl)-2,3-dihydro-2-oxo-3-(2-thienyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN


(Continued)



RN 767304-29-0 CAPLUS
CN 1H-Benzimidazole-1-acetamide, N-(1',3'-dihydro-3-methyl-2,5-dioxospiro(imidazolidine-4,2'-(2H)inden)-5'-yl)- (9CI) (CA INDEX NAME)




RN 767304-30-3 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine-1-acetamide, N-(1',3'-dihydro-3-methyl-2,5-dioxospiro(imidazolidine-4,2'-(2H)inden)-5'-yl)-2,3-dihydro-2-oxo-3-phenyl- (9CI) (CA INDEX NAME)




RN 767304-31-4 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine-1-acetamide, N-(1',3'-dihydro-3-methyl-2,5-dioxospiro(imidazolidine-4,2'-(2H)inden)-5'-yl)-2,3-dihydro-2-oxo-3-(phenylmethyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)




RN 767304-32-5 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine]-1(2H)-acetamide, N-(1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-2-oxo-1'-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 767304-33-6 CAPLUS
CN Benzoic acid, 4-[3-[2-((1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)amino)-2-oxoethyl]-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-, ethyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)




RN 767304-34-7 CAPLUS
CN Benzoic acid, 4-[3-[2-((1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)amino)-2-oxoethyl]-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 767304-35-8 CAPLUS
CN 1H-Benzimidazole-1-acetamide, N-(1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-2,3-dihydro-3,4,6-trimethyl-2-oxo- (9CI) (CA INDEX NAME)

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN


(Continued)




RN 767304-36-9 CAPLUS
CN 1H-Benzimidazole-1-acetic acid, 3-[2-((1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)amino)-2-oxoethyl]-2,3-dihydro-5,7-dimethyl-2-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 767304-37-0 CAPLUS
CN 1H-Benzimidazole-1-acetic acid, 3-[2-((1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)amino)-2-oxoethyl]-2,3-dihydro-5,7-dimethyl-2-oxo- (9CI) (CA INDEX NAME)



RN 767304-38-1 CAPLUS
CN 1H-Benzimidazole-1,3(2H)-diacetamide, N1-(1',3'-dihydro-3-methyl-2,5-

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-4,6-dimethyl-2-oxo- (9CI) (CA INDEX NAME)


RN 767304-39-2 CAPLUS
CN 1H-Benzimidazole-1,3(2H)-diacetamide, N1-(1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-N3,N3,4,6-tetramethyl-2-oxo- (9CI) (CA INDEX NAME)




RN 767304-40-5 CAPLUS
CN 1H-Benzimidazole-1-acetamide, N-(1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-2,3-dihydro-3-[4-(methylthio)-2-thiazolyl]-2-oxo- (9CI) (CA INDEX NAME)

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)




RN 767304-41-6 CAPLUS
CN 1H-Benzimidazole-1-acetamide, N-(1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-2,3-dihydro-3-[4-(methylsulfinyl)-2-thiazolyl]-2-oxo- (9CI) (CA INDEX NAME)




RN 767304-42-7 CAPLUS
CN 1H-Benzimidazole-1-acetamide, N-(1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-2,3-dihydro-3-[4-(methylsulfonyl)-2-thiazolyl]-2-oxo- (9CI) (CA INDEX NAME)

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)




RN 767304-45-0 CAPLUS
CN 1H-Benzimidazole-1-acetamide, 3-[5-(aminocarbonyl)-2-pyridinyl]-N-(1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 767304-46-1 CAPLUS
CN 1H-Benzimidazole-1-acetamide, N-(1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-3-(4-methoxy-2-pyrimidinyl)-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)




RN 767304-43-8 CAPLUS
CN 1H-Benzimidazole-1-acetamide, N-(1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-3-[4-(dimethylamino)carbonyl]-2-thiazolyl]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 767304-44-9 CAPLUS
CN 1H-Benzimidazole-1-acetamide, 3-(3,5-difluorophenyl)-N-(1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)




RN 767304-47-2 CAPLUS
CN 1H-Benzimidazole-1-acetamide, N-(1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-3-(2-methyl-5-pyrimidinyl)-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 767304-48-3 CAPLUS
CN 1H-Benzimidazole-1-acetamide, 6-bromo-N-(1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-2,3-dihydro-2-oxo-3-(2-pyridinyl)- (9CI) (CA INDEX NAME)


L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)



RN 767304-49-4 CAPLUS

CN 1H-Benzimidazole-1-acetamide, 6-cyano-N-(1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-2,3-dihydro-2-oxo-3-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 767304-50-7 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-1-acetamide, 3-cyclohexyl-N-(1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)


L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)



RN 767304-51-8 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-1-acetamide, N-(1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-2,3-dihydro-2-oxo-3-(tetrahydro-3-furanyl)- (9CI) (CA INDEX NAME)




RN 767304-52-9 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-1-acetamide, N-(1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-2,3-dihydro-3-[1-(methylsulfonyl)-3-pyrrolidinyl]-2-oxo- (9CI) (CA INDEX NAME)


L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)



RN 767304-53-0 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-1-acetamide, 3-(1-(cyclopropylcarbonyl)-3-pyrrolidinyl)-N-(1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 767304-54-1 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-1-acetamide, N-(1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-2,3-dihydro-3-(1-methyl-2-oxo-3-pyrrolidinyl)-2-oxo- (9CI) (CA INDEX NAME)


L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)



RN 767304-55-2 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-1-acetamide, N-(1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-2,3-dihydro-2-oxo-3-(tetrahydro-1,1-dioxido-3-thienyl)- (9CI) (CA INDEX NAME)




RN 767304-56-3 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine-1-acetamide, N-(1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN


(Continued)



RN 767304-57-4 CAPLUS
CN 1H-Indole-1,3-diacetamide, N-(1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-N3,N3-dimethyl-α3-oxo- (9CI) (CA INDEX NAME)




RN 767304-58-5 CAPLUS
CN 1H-Benzimidazole-1-acetamide, N-(1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-6-fluoro-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)

RN 767304-59-6 CAPLUS
CN 1H-Benzimidazole-1-acetamide, N-(1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-2,3-dihydro-2-oxo-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 767304-60-9 CAPLUS
CN 1H-Benzimidazole-1-acetamide, N-(1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-4-(2-fluorophenyl)-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 767304-61-0 CAPLUS
CN 1H-Benzimidazole-1-butanimide, 3-[2-(1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)amino]-2-oxoethyl)-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)




RN 767304-62-1 CAPLUS
CN 1H-Benzimidazole-1-acetamide, N-(1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-3-(2-(cyclopropoxyethoxyethyl)-N-(1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 767304-63-2 CAPLUS
CN 1H-Benzimidazole-1-acetamide, N-[6'-chloro-1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl]-2,3-dihydro-2-oxo-3-(2-pyridinyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)




RN 767304-64-3 CAPLUS
CN 1H-Benzimidazole-1-acetamide, N-(4'-chloro-1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-2,3-dihydro-2-oxo-3-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 767304-65-4 CAPLUS
CN 1H-Benzimidazole-1-acetamide, N-[1',3'-dihydro-2,5-dioxo-3-(phenylmethyl)spiro[imidazolidine-4,2'-(2H)inden]-5'-yl]-2,3-dihydro-2-oxo-3-(2-pyridinyl)- (9CI) (CA INDEX NAME)


L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)



RN 767304-66-5 CAPLUS

CN 1H-Benzimidazole-1-acetamide, N-[1',3'-dihydro-3-(2-methylpropyl)-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl]-2,3-dihydro-2-oxo-3-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 767305-84-0 CAPLUS

CN 3(2H)-Benzoxazoleacetamide, 5-chloro-N-(3',4'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(1'H)-naphthalen]-7'-yl)-2-oxo- (9CI) (CA INDEX NAME)


L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)



RN 767305-85-1 CAPLUS

CN 1H-Benzimidazole-1-acetamide, N-(3',4'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(1'H)-naphthalen]-7'-yl)-2,3-dihydro-3-methyl-2-oxo- (9CI) (CA INDEX NAME)



10/549,338 & 10/547,227

12/13/2006

=> d ibib abs hitstr L7 1-7

12/13/2006


L7 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2006:1070147 CAPLUS
 DOCUMENT NUMBER: 145:419134
 TITLE: Constrained indazoloazepinones and related compounds as CGRP-receptor antagonists and their preparation, pharmaceutical compositions, and use for treatment of migraine
 INVENTOR(S): Chaturvedula, Prasad V.; Mercer, Stephen E.; Fang, Haiquan
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 140pp., Cont.-in-part of U.S.
 Ser. No. 247,697.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:
 PRIORITY APPLN. INFO.:
 PATENT NO. KIND DATE APPLICATION NO. DATE
 US 2006229447 A1 20061012 US 2006-417326 20060503
 US 2006094707 A1 20060504 US 2005-247697 20051011
 P 2004-624655P P 20041103
 X
 US 2005-678099P P 20050505
 US 2005-247697 A2 20051011
 X
 OTHER SOURCE(S): MARPAT 145:419134
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists of formula I, methods for identifying them, pharmaceutical compns. comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors. Compds. I (R1 = (halo)alkyl, alkenyl, cycloalkyl, etc.; R2 = H, halo, OH, alkyl, etc.; R3 = H, OH, halo, alky, or alkenyl; or R2R3 together are CHNNR5; R4 = H, halo, alky, or alkenyl; R5 = H or alkyl; R6 = H, alkyl, or spiro[imidazolidinedione-cycloalkaphenyl]; or NR5R6 taken together = (un)substituted 6-membered aza-cycle, or spiro-substituted piperidine; X-Y = aminocarbonyl, oxycarbonyl, methylenecarbonyl, ethylene, or amino(cyano)iminomethyl; n = 0-1; and their pharmaceutically acceptable salts or solvates thereof) were prepared. Thus, compound II was prepared by

L7 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 substitution of (9-benzyl-4-chloro-8-oxo-3,6,7,8,9,10-hexahydro-2,3,9-triaza-(8)-cyclohepta[e]inden-7-yl)carbamic acid benzyl ester with 4-(2-oxo-1,4-dihydro-2H-quinoxolin-3-yl)piperidine. Compds. I were evaluated for their CGRP receptor binding activity. It was detd. that most of the invention compds. exhibited CGRP receptor activity. For example, II was found to have an IC50 value between 0.1-10 nM against CGRP receptors and for cAMP functions. Compds. I are claimed to be useful for treatment migraine.
 IT 885607-70-5P 885607-71-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of constrained indazoloazepinones and related compds. as CGRP-receptor antagonists for treatment of migraine)
 RN 885607-70-5 CAPLUS
 CN Pyrazolo[3,4-i][2]benzazepine-7-acetamide, 4-chloro-N-(3',4'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(1'H)-naphthalen]-6'-yl)-9-(2,2-dimethylpropyl)-3,6,7,8,9,10-hexahydro-8-oxo-, (7S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-71-6 CAPLUS
 CN Pyrazolo[3,4-i][2]benzazepine-7-acetamide, 4-chloro-N-(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-9-(2,2-dimethylpropyl)-3,6,7,8,9,10-hexahydro-8-oxo-, (7S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2006:409732 CAPLUS
 DOCUMENT NUMBER: 144:450702
 TITLE: Constrained indazoloazepinones and related compounds as CGRP-receptor antagonists and their preparation, pharmaceutical compositions, and use for treatment of migraine
 INVENTOR(S): Chaturvedula, Prasad V.; Mercer, Stephen E.; Fang, Haiquan
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 112 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006094707	A1	20060504	US 2005-247697	20051011
WO 2006052378	A1	20060518	WO 2005-US26659	20051012
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, ST, TO, TM, TN, TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TC, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, T2, UG, ZM, ZW, AM, AZ, BY, KG, KZ, RU, TJ, TM				
US 2006229447	A1	20061012	US 2006-417326	20060503
PRIORITY APPLN. INFO.:			US 2004-624655P	P 20041103
			US 2005-678099P	P 20050505
			US 2005-247697	A 20051011

OTHER SOURCE(S): MARPAT 144:450702
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists of formula I, methods for identifying them, pharmaceutical compns. comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors. Compds. of formula I, wherein R1 is C1-6 (halo)alkyl, C2-6 alkenyl, C3-7 cycloalkyl, C5-7 cyclalkenyl, C1-6(C3-7 cycloalkenyl)alkyl,

L7 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 Cl-6(Cl-6alkoxy)alkyl, Cl-6(hetero)arylalkyl, Cl-6(NH₂)alkyl and derivs., NH-pyrrolidinyl and derivs., or NH-piperidinyl and derivs.; R2 is H, halo,

OH, Cl-6 alkyl, C2-6 alkenyl, BnO, or NH₂ and derivs.; R3 is H, OH, halo, Cl-6 alkyl, or C2-6 alkenyl; or R2R3 together are CHNNR₅; R4 is H, halo, Cl-6 alkyl, or C2-6 alkenyl; R5 is H or Cl-6 alkyl; R6 is H, Cl-6 alkyl, or spiro[imidazolidine-4,2'-(2H)inden]-5'-yl; or NR5R6 taken together is (un)substituted 6-membered aza-cycle, or spiro-substituted piperidine;

X-Y is aminocarbonyl, oxy carbonyl, methylene carbonyl, ethylene, or amine(cyano)imino(methyl); n is 0 or 1; and their pharmaceutically acceptable salts or solvates thereof are claimed. Example compd. II was prep'd. by substitution of:

(9-benzyl-4-chloro-8-oxo-3,6,7,8,9,10-hexahydro-2,3,9-triaza(1*N*)-cyclohepta[elinden-7-yl]carbamic acid benzyl ester with 4-(2-oxo-1,4-dihydro-2H-quinoxolin-2-yl)piperidine. All the invention compds. were evaluated for their CGRP receptor binding activity. From the

assay, it was detd. that most of the invention compds. exhibited CGRP receptor activity. Example compd. II were found to have an IC₅₀ value between 0.1-10 nM against CGRP receptors and for cAMP functions. These compds. are claimed to be useful for treatment migraine.


IT 885607-71-6P 885607-71-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate: preparation of constrained indazoloazepinones and related compds. as CGRP-receptor antagonists and useful for treatment of migraine).

RN 885607-70-5 CAPLUS
 CN Pyrazolo[3,4-1][2]benzazepine-7-acetamide, 4-chloro-N-(3',4'-dihydro-2,5-dioxospiro[imidazolidine-4,2'(1'H)-naphthalen-6'-yl]-9-(2,2-dimethylpropyl)-3,6,7,8,9,10-hexahydro-8-oxo-, (7S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 885607-71-6 CAPLUS

CN Pyrazolo[3,4-1][2]benzazepine-7-acetamide, 4-chloro-N-(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-9-(2,2-dimethylpropyl)-3,6,7,8,9,10-hexahydro-8-oxo-, (7S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:315123 CAPLUS

DOCUMENT NUMBER: 144:460321

TITLE: Non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead

AUTHOR(S): Williams, Theresa M.; Stumm, Daniel A.; Nguyen, Diem N.; Quigley, Amy G.; Bell, Ian M.; Gallicchio, Steven N.; Zartman, C. Blake; Wan, Bang-Lin; Della Penna, Kimberly; Kunapuli, Priya; Kahr, Stefanie A.; Kobian, Ken S.; Mosser, Scott D.; Rutledge, Ruth Z.; Salvatore, Christopher; Fay, John F.; Varga, Joseph P.; Graham, Samuel L.

CORPORATE SOURCE: Department of Medicinal Chemistry, Merck & Co., West Point, PA, 19486, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(10), 2595-2598

CODEN: BMCLB; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 144:460321

AB High-throughput screening of the Merck sample collection identified a benzodiazepinone tetralin-spirohydantoin as a CGRP receptor antagonist with micromolar activity. Comparing the structure of this compound with those of earlier peptide-based antagonists such as BIBN 4096 BS, a key hydrogen bond donor-acceptor pharmacophore was hypothesized. Subsequent structure activity studies supported this hypothesis and led to benzodiazepinone piperidinyldihydroquinoxolinone, CGRP receptor Ki = 44

nM and IC₅₀ = 38 nM. This compound was orally bioavailable in rats and is a lead in the development of orally bioavailable CGRP antagonists for the treatment of migraine.


IT 886854-32-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead in relation to treatment of migraine)

RN 886854-32-6 CAPLUS

CN Urea, N-(3',4'-dihydro-2,5-dioxospiro[imidazolidine-4,2'(1'H)-naphthalen]-6'-yl)-N'-[(3R)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS

FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L7 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:857553 CAPLUS
DOCUMENT NUMBER: 141:332225

TITLE: Preparation of benzodiazepine spirohydantoin CGRP receptor antagonists
INVENTOR(S): Bell, Ian M.; Graham, Samuel L.; Williams, Theresa M.; Stump, Craig A.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087649	A2	20041014	WO 2004-US7715	20040310
WO 2004087649	A3	20050630		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MN, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004226018	A1	20041014	AU 2004-226018	20040310
CA 2519515	AA	20041014	CA 2004-2519515	20040310
EP 1606286	A2	20051221	EP 2004-749375	20040310
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
US 20061895600	A1	20060824	US 2005-547228	20050826
			US 2003-435611P	P 20030314

PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 141:332225
GI

L7 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
acceptable salts, are antagonists of CGRP receptors and are useful in the treatment or prevention of diseases in which the CGRP is involved, such as

headache, migraine and cluster headache. Thus, e.g., II was prepd. by amidation of 6'-carboxy-3',4'-dihydro-1'H-spiro[imidazolidine-4,2'-naphthalene]-2,5-dione (prepn. given) with (3R)-3-amino-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-2,3-dihydro-1H-1,4-benzodiazepine. Compds. of the invention had activity as antagonists of the CGRP receptor with a Ki or IC₅₀ value of less than about 50 nM. The invention is also directed to pharmaceutical compns. comprising these compds. and the use of these compds. and compns. in the prevention or treatment of such diseases in which CGRP is involved.

IT 773146-85-3P 773146-86-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of benzodiazepine spirohydantoin derivs.)


as (CGRP receptor antagonists)

RN 773146-85-3 CAPLUS

CN Urea,

N-(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-N'-(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 773146-86-4 CAPLUS

CN Urea,


N-(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-N'-(3R)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I (R1 = H, (un)substituted-alkyl, -heterocycle, -Ph, or cycloalkyl; R2a, R2b, and R2c independently = H, halo, OH, CF3O, (un)substituted-alkyl, etc.) R3 = H, (un)substituted-alkyl, -cycloalkyl, -heterocycle, or -phenyl; R4 = H, Ph, PhCH₂, cycloalkyl, (un)substituted alkyl; R6 = H, (un)substituted-alkyl, -cycloalkyl, -heterocycle, or -phenyl; X = bond or NR4a wherein R4a is independently selected from definitions for R4; m = 1-2; n = 1-2], as well as their pharmaceutically

L7 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



check against (B)

L7 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:802712 CAPLUS

DOCUMENT NUMBER: 141:314331

TITLE: Preparation of aryl-fused spirohydantoin as calcitonin gene-related peptide (CGRP) receptor antagonists

INVENTOR(S): Bell, Ian M.; Theberge, Cory R.; Zhang, Xu-fang; Zartman, C. Blair

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 66 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 200408270	A1	20040930	WO 2004-US7686	20040310
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004222328	A1	20040930	AU 2004-222328	20040310
CA 2518843	AA	20040930	CA 2004-2518843	20040310
EP 1605936	A1	20051221	EP 2004-719322	20040310
R: AT, BE, CH, DE, DK, ES, FR, GR, HU, IE, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
JP 2006520388	T2	20060907	JP 2006-507140	20040310
US 2006189593	A1	20060824	US 2005-547227	20050826
			US 2003-454917P	P 20030314

PRIORITY APPLN. INFO.: WO 2004-US7686 W 20040310



OTHER SOURCE(S): MARPAT 141:314331

GI

Instant + App?

L7 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)




AB Title compds. [I; B = (substituted) cycloalkyl, Ph, naphthyl, indanyl, indolyl, biphenyl, phenanthrenyl, anthryl, chromanyl, isochromanyl, oxadiazolyl, azetidinyl, azepanyl, imidazolyl, piperazinyl, pyrazinyl, benzoxazolyl, isoquinolinyl, dibenzofuryl, isoindolyl, pyrrolyl, benzofurazolyl, benzothiazolyl, furyl, tetrahydrofuryl, thiazolyl, pyrazolyl, pyrimidinyl, triazolyl, tetrazolyl, etc., A1, A2 = bond, CR1R14, NR10, CR1R14NR10, etc.; R10 = H, (fluorocarbonyl), cycloalkyl, Ph, PhCH2, etc.; R13, R14 = H, (fluoroalkyl), alkyl, alkoxy, OCF3, CF3, halo, OH, cyano; R6 = H, (substituted) alkyl, cycloalkyl, Ph, pyridyl, pyrimidinyl, pyrazinyl, thiophenyl, morpholinyl; m, n = 1, 2], were prepared. Thus, 3-chlorobenzoic acid, 6'-amino-3',4'-dihydro-1'-spiro[imidazolidine-4,2'-naphthalene]-2,5-dione (preparation given), EDC, HOBT, and diisopropylethylamine were stirred 18 h in DMF at ambient temperature to give title compound (II). I antagonized CGRP receptors with activities generally less than about 50 μ M.

IT 765940-94-1P 765940-95-2P 765940-96-3P
765940-98-5P 765941-00-2P 765941-02-4P
765941-03-5P 765941-04-6P 765941-06-8P
765941-07-9P 765941-08-0P 765941-09-1P
765941-13-7P 765941-15-9P 765941-17-1P
765941-18-2P 765941-19-3P 765941-20-6P
765941-22-8P 765941-24-0P 765941-26-2P
765941-28-4P 765941-30-8P 765941-32-0P
765941-33-1P 765941-35-3P 765941-37-5P
765941-39-7P 765941-41-1P 765941-43-3P
765941-45-5P 765941-47-7P 765941-49-9P
765941-51-3P 765941-53-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic Use); BIOL (Biological study); PREP (Preparation); USES

L7 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN


(Continued)




RN 765941-00-2 CAPLUS
CN 1-Naphthaleneacetamide, N-(3',4'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(1'H)-naphthalen]-6'-yl) (9CI) (CA INDEX NAME)



RN 765941-02-4 CAPLUS
CN 5-Quinolinecarboxamide, N-(3',4'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(1'H)-naphthalen]-6'-yl) (9CI) (CA INDEX NAME)



RN 765941-03-5 CAPLUS
CN Urea, N-(3',4'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(1'H)-naphthalen]-6'-yl)-N'-1-naphthalenyl (9CI) (CA INDEX NAME)



RN 765941-04-6 CAPLUS
CN Cyclopropanecarboxamide, N-(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(1'H)-naphthalen]-6'-yl) (9CI) (CA INDEX NAME)


L7 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

(Uses)

(prepn. or aryl-fused spirohydantoins as calcitonin gene-related peptide receptor antagonists)


RN 765940-94-1 CAPLUS

CN Benzamide, 3-chloro-N-(3',4'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(1'H)-naphthalen]-6'-yl) (9CI) (CA INDEX NAME)




RN 765940-95-2 CAPLUS

CN Benzamide, 4-cyano-N-(3',4'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(1'H)-naphthalen]-6'-yl) (9CI) (CA INDEX NAME)



RN 765940-96-3 CAPLUS

CN 2-Quinoxalinecarboxamide, N-(3',4'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(1'H)-naphthalen]-6'-yl) (9CI) (CA INDEX NAME)




RN 765940-98-5 CAPLUS

CN Benzamide, N-(3',4'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(1'H)-naphthalen]-6'-yl)-3,5-dimethoxy- (9CI) (CA INDEX NAME)

L7 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


L7 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
4,2'-(2H)inden]-5'-yl)-2-phenyl-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 765941-06-8 CAPLUS

CN Benzenepropanamide, N-(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl) (9CI) (CA INDEX NAME)




RN 765941-07-9 CAPLUS

CN Cyclopentanepropanamide, N-(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl) (9CI) (CA INDEX NAME)



RN 765941-08-0 CAPLUS


CN Benzamide, N-(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-3,5-dimethoxy- (9CI) (CA INDEX NAME)




RN 765941-09-1 CAPLUS

CN 4-Quinolinecarboxamide, 2-cyclopropyl-N-(1',3'-dihydro-2,5-


L7 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
dioxospiro(imidazolidine-4,2'-(2H)inden]-5'-yl)- (9CI) (CA INDEX NAME)



RN 765941-13-7 CAPLUS
CN 1H-Indene-1-carboxamide, N-(1',3'-dihydro-2,5-dioxospiro(imidazolidine-4,2'-(2H)inden]-5'-yl)-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 765941-15-9 CAPLUS
CN 3-Pyridineacetamide, 5-bromo-N-(1',3'-dihydro-2,5-dioxospiro(imidazolidine-4,2'-(2H)inden]-5'-yl)- (9CI) (CA INDEX NAME)




RN 765941-17-1 CAPLUS
CN 3-Pyridineacetamide, 5-(2-chlorophenyl)-N-(1',3'-dihydro-2,5-dioxospiro(imidazolidine-4,2'-(2H)inden]-5'-yl)- (9CI) (CA INDEX NAME)


L7 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 765941-18-2 CAPLUS
CN Urea, N-[3-chlorophenyl)methyl]-N'-(1',3'-dihydro-2,5-dioxospiro(imidazolidine-4,2'-(2H)inden]-5'-yl)- (9CI) (CA INDEX NAME)



RN 765941-19-3 CAPLUS
CN Urea, N-[4-chlorophenyl)methyl]-N'-(1',3'-dihydro-2,5-dioxospiro(imidazolidine-4,2'-(2H)inden]-5'-yl)- (9CI) (CA INDEX NAME)




RN 765941-20-6 CAPLUS
CN Urea, N-[3,5-difluorophenyl)methyl]-N'-(1',3'-dihydro-2,5-dioxospiro(imidazolidine-4,2'-(2H)inden]-5'-yl)- (9CI) (CA INDEX NAME)




L7 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 765941-22-8 CAPLUS
CN Urea, N-[2,6-difluorophenyl)methyl]-N'-(1',3'-dihydro-2,5-dioxospiro(imidazolidine-4,2'-(2H)inden]-5'-yl)- (9CI) (CA INDEX NAME)



RN 765941-24-0 CAPLUS
CN Urea, N-[2,6-dichlorophenyl)methyl]-N'-(1',3'-dihydro-2,5-dioxospiro(imidazolidine-4,2'-(2H)inden]-5'-yl)- (9CI) (CA INDEX NAME)




RN 765941-26-2 CAPLUS
CN Urea, N-(1',3'-dihydro-2,5-dioxospiro(imidazolidine-4,2'-(2H)inden]-5'-yl)-N'-(8-quinolinylmethyl)- (9CI) (CA INDEX NAME)




RN 765941-28-4 CAPLUS
CN Urea, N-(3-acetylphenyl)-N'-(1',3'-dihydro-2,5-dioxospiro(imidazolidine-4,2'-(2H)inden]-5'-yl)- (9CI) (CA INDEX NAME)


L7 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 765941-30-8 CAPLUS
CN Urea, N-(1',3'-dihydro-2,5-dioxospiro(imidazolidine-4,2'-(2H)inden]-5'-yl)-N'-(4-fluorophenyl)methyl)- (9CI) (CA INDEX NAME)



RN 765941-32-0 CAPLUS
CN Urea, N-(1',3'-dihydro-2,5-dioxospiro(imidazolidine-4,2'-(2H)inden]-5'-yl)-N'-(2-fluorophenyl)methyl)- (9CI) (CA INDEX NAME)




RN 765941-33-1 CAPLUS
CN Urea, N-(1',3'-dihydro-2,5-dioxospiro(imidazolidine-4,2'-(2H)inden]-5'-yl)-N'-(3-fluorophenyl)methyl)- (9CI) (CA INDEX NAME)




RN 765941-35-3 CAPLUS
CN Urea, N-(1',3'-dihydro-2,5-dioxospiro(imidazolidine-4,2'-(2H)inden]-5'-yl)-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)




RN 765941-37-5 CAPLUS
CN 1-Naphthalenesulfonamide, N-(1',3'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)- (9CI) (CA INDEX NAME)



RN 765941-39-7 CAPLUS
CN Cyclop propane carboxamide, N-(1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-2-phenyl-, (1R,2R)-rel-(9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 765941-41-1 CAPLUS
CN Benzene propanamide, N-(1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)- (9CI) (CA INDEX NAME)

L7 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN


(Continued)




RN 765941-43-3 CAPLUS
CN Cyclopentane propanamide, N-(1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)- (9CI) (CA INDEX NAME)



RN 765941-45-5 CAPLUS
CN Benzamide, 3,5-dibromo-N-(1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)- (9CI) (CA INDEX NAME)



RN 765941-47-7 CAPLUS
CN Cyclohexane propanamide, N-(1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)- (9CI) (CA INDEX NAME)



RN 765941-49-9 CAPLUS


L7 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
ACCESSION NUMBER: 2004-799568 CAPLUS
DOCUMENT NUMBER: 141:314326
TITLE: Preparation of spirohydantoin anilides as calcitonin gene-related peptide (CGRP) receptor antagonists
INVENTOR(S): Bell, Ian M.; Theberge, Cory R.; Williams, Theresa M.; Zaritman, C. Blair; Zhang, Xu-fang; Gallicchio, Steven

PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 61 pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 20040930	A1	20040930	WO 2004-US7678	20040310
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, US, U2, VC, VN, YU, ZA, ZM, ZW, RW: BM, GH, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, C2, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004221891	A1	20040930	AU 2004-221891	20040310
CA 2518852	AA	20040930	CA 2004-2518852	20040310
EP 1606264	A1	20051221	EP 2004-719323	20040310
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, T2				
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
JP 2006520387	T2	20060907	JP 2006-507138	20040310
US 2006148779	A1	20060746	US 2005-547082	20050826
			US 2003-454944P	P 20030314
			WO 2004-US7678	A 20040310

OTHER SOURCE(S): MDRPAT 141:314326
GI


RN 765941-51-3 CAPLUS
CN Propanamide, N-(1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-3-phenoxy- (9CI) (CA INDEX NAME)



RN 765941-53-5 CAPLUS
CN 2-Propynamide, N-(1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-3-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



AB Title compds. (I): B = (substituted) imidazolyl, pyrrolyl, pyrazolyl.

Searched by Jason M. Nolan, Ph.D.

Page 28

B *hmm - N*
monoacyl


L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 triazolyl, 2-oximidazolyl, 2-oxooxazolyl, 2-oxothiazolyl,
 2-oxodiazepenyl, etc.; A1, A2 = bond, CR13R14, nuli; R13, R14 = H,
 (fluoro)alkyl, OH; R4 = H, (fluoro)alkyl; R5a, R5b, R5c = H, alkyl,
 alkoxy, OCF₃, CF₃, halo, OH, cyano; R6 = H, (substituted) alkyl, Ph,
 pyridyl, pyrimidinyl, pyrazinyl, thiienyl; m, n = 1, 2], were prepd.

Thus, 3-chlorobenzoic acid,

6'-amino-3',4'-dihydro-1'H-spiro[imidazolidine-4,2'-naphthalene]-2,5-dione, EDC, HOBT, and diisopropylamine were stirred together for 18 h in DMF at ambient temp. to give 6'-(3-chlorobenzoyl)amino-3',4'-dihydro-1'H-spiro[imidazolidine-4,2'-naphthalene]-2,5-dione. It generally showed CGRP antagonistic activity with K_i or IC₅₀ values of ≤50 nM.

IT 765940-94-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (claimed compound; preparation of spirohydantoin anilides as calcitonin gene-related peptide receptor antagonists)

RN 765940-94-1 CAPLUS
 CN Benzamide, 3-chloro-N-(3',4'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(1'H)-naphthalen]-6'-yl)- (9CI) (CA INDEX NAME)



- claim 15

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L7 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 2004:768443 CAPLUS
 141:14324
 Preparation of bicyclic anilide spirohydantoin CGRP receptor antagonists
 Bell, Ian M.; Gallicchio, Steven N.; Theberge, Cory S.; Zhang, Yu-Fang; Stump, Craig; Zartman, C. Blair
 Merck & Co., Inc., USA
 PCT Int Appl., 120 pp.
 CODEN: PIXXD2
 Instant App


DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE :
WO 2004082605	A2	20040930	WO 2004-U97289	20040310.
WO 2004082605	A3	20041118		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004222383	A1	20040930	AU 2004-222383	20040310
CA 2519475	AA	20040930	CA 2004-2519475	20040310
EP 1608627	A2	20051228	EP 2004-719222	20040310
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
JP 2006520383	T2	20060907	JP 2006-507033	20040310
US 2006211712	A1	20060921	US 2005-549338	20050913
			US 2003-455609P	20030314
			US 2003-486642P	P 20030711
			WO 2004-U97289	A 20040310


OTHER SOURCE(S): MARPAT 141:314324
 GI

L7 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L7 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



B thru N




AB The title compds. [I]; B = (un)substituted bicyclic heterocycles; A1, A2 = a bond, (un)substituted CH₂; R4 = H, alkyl, fluoroalkyl, cycloalkyl, etc.; R51, R52, R53 = H, alkyl, alkoxy, etc.; R6 = H, alkyl, cycloalkyl, etc.; m, n = 1-2] that are antagonists of CGRP receptors and that are useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache, were prepared. E.g., a multi-step synthesis of II, starting from 6-bromo-2-tetralone, was given. The exemplified compds. had activity as antagonists of the CGRP receptor, generally with a K_i or IC₅₀ value of <50 μM. The invention is also directed to pharmaceutical compns. comprising the compds. I and use of these compds. and compns. in the prevention or treatment of such diseases in which CGRP is involved.

IT 765940-94-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (preparation of bicyclic anilide spirohydantoin CGRP receptor antagonists)

RN 765940-94-1 CAPLUS

CN Benzamide, 3-chloro-N-(3',4'-dihydro-2,5-dioxospiro[imidazolidine-4,2'-(1'H)-naphthalen]-6'-yl)- (9CI) (CA INDEX NAME)



- claim 24